BioMedNewsBreaks

ThursdayMar 17, 2022 11:09 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Makes Changes in Management

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has announced changes in company leadership. According to the announcement, InMed chief financial officer Bruce Colwill is retiring, effective March 31, 2022; Colwill will serve as an advisor to the company through June 30, 2022, to ensure a smooth transition. The company has appointed Brenda Edwards as interim CFO while the company searches for a full-time replacement. Edwards has garnered more than 35 years experience to her new position, including more than two decades of experience as a chief financial officer; she has served…

Continue Reading

WednesdayMar 16, 2022 2:26 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Launching Additional Rare Cannabinoids in Response to Inbound Demand

InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and manufacturing technologies for pharmaceutical-grade rare cannabinoids, has dedicated itself to developing new therapeutic alternatives for the treatment of conditions with high unmet medical needs. The manufacturing process used by InMed and its recently acquired subsidiary BayMedica is unparalleled in the industry. “There is no ‘one-size-fits-all’ approach to cannabinoid manufacturing, so multiple avenues are required to realize the maximum outcome for the targeted cannabinoid. InMed and BayMedica, like a well-oiled machine, work together using biosynthesis, chemical synthesis and the proprietary IntegraSyn(TM) manufacturing models,” a recent article explains. “Together,…

Continue Reading

TuesdayMar 15, 2022 10:51 am

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Secures Medical Device Registration in New Zealand for Proprietary IoT System

RYAH Group (CSE: RYAH) today announced that its subsidiary, RYAH Medtech Inc., has received a medical device certification in New Zealand for its proprietary Internet of Things (“IoT”) powered medical cannabis inhaler, proprietary cartridges and software application associated with the device (the “RYAH Smart Medical Inhaler System”). This comes in coordination with Medical Kiwi Ltd. as local sponsor for the New Zealand certification. Medical Kiwi is a New Zealand-based leader in R&D, manufacturing, cultivation and distribution of medical cannabis and medical devices. “We are pleased to continue gaining traction with medical device registration around the world and are excited to…

Continue Reading

FridayMar 11, 2022 3:11 pm

BioMedNewsBreaks – Nemaura Medical Inc.’s (NASDAQ: NMRD) Revolutionary sugarBEAT(R) CGM Device Met with Early Success

Nemaura Medical (NASDAQ: NMRD), a medical technology company, has sought to develop and offer economical, compact and convenient non-invasive devices that could alleviate the pain associated with frequent skin pricking among diabetic patients. The devices also simultaneously promote routine glucose testing in a bid to control blood glucose levels more effectively. Nemaura offers two flagship constant glucose monitoring (“CGM”) products: the sugarBEAT(R), a non-invasive wearable diagnostic device, and MiBoKo, an application that supports personalized lifestyle coaching programs. A recent article reads: “The company’s revolutionary sugarBEAT(R) CGM device seeks to provide users with non-invasive glucose monitoring; as described by the company,…

Continue Reading

FridayMar 11, 2022 1:25 pm

BioMedNewsBreaks – AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) Announces Collaboration Agreement with RCFFN, University of Manitoba

AREV Life Sciences (CSE: AREV) (OTC: AREVF) has announced its engagement of the University of Manitoba, Richardson Centre for Functional Foods and Nutraceuticals (“RCFFN”) to complete the design and produce the prototypes of its Superior Utility Supplementation Therapeutic Agent for Indicated Nutritional Needs “SUSTAINN,” AREV’s next-generation Ready to Use Therapeutic Food (“RUTF”). According to the announcement, AREV, through its U.S. subsidiary in Rochester, New York, is developing the aflatoxin-free RUTF for the treatment of SAM leading to inanition. AREV’s SUSATAINN is being developed in collaboration with representatives from several academic research institutions, including the Institute for Human Virology (“IHV”), The…

Continue Reading

ThursdayMar 10, 2022 11:28 am

BioMedNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Strengthening Leadership Role in Psychedelics Space

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) is a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders. The company recently made two announcements that show a more immediate response to providing mental health solutions, further strengthening its leadership role in the psychedelic drugs market. First, Mydecine announced that Health Canada had included the dealer’s license, under which the company operates, as a supplier for the Special Access Program (“SAP”). “SAP allows healthcare providers to seek specific drugs normally unavailable for sale in Canada for patients with serious or life-threatening conditions who are not responding…

Continue Reading

WednesdayMar 09, 2022 12:40 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reiterates Progress for Lead Product Candidate, Addresses Recent Share Price Activity in Video to Shareholders

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today released a video to shareholders that reiterates its operational and clinical progress for lead product candidate, Berubicin, and addresses recent share price activity. “The divergence that exists between our operational strength and share price is top of mind for myself and the whole team at CNS Pharmaceuticals. As a shareholder of CNS Pharma, I share in the frustrations as it pertains to the share price and fluctuation in the market – both…

Continue Reading

TuesdayMar 08, 2022 1:28 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at 34th Annual Roth Conference

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced that its president and CEO Eric A. Adams will be presenting at the 34th Annual Roth Conference being held March 13-15, 2022. Adams will host a fireside chat with Scoth Henry, managing director and head of pharmaceuticals research at Roth Capital Partners, on Tuesday, March 15. In addition to the live fireside chat, InMed’s virtual Roth Conference presentation is now available on-demand by visiting https://ibn.fm/fsWdF. A webcast will be made available to investors following the event in the investor relations section of…

Continue Reading

TuesdayMar 08, 2022 12:23 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Secures Approval from Health Canada Recognizing RYAH Smart Medical Inhaler System as Medical Device

RYAH Group (CSE: RYAH) today announced that its subsidiary, RYAH Medtech Inc., has received a Health Canada Medical Device License (“MDL”) for its proprietary Internet of Things (“IoT”) powered medical cannabis inhaler, proprietary cartridges and software application associated with the device (the “RYAH Smart Medical Inhaler System”). According to the update, Health Canada License number 107475 allows RYAH to market its Smart Medical Inhaler System to medical patients in Canada and potentially represents a significant boost to RYAH’s growth strategy. “The approval from Health Canada recognizing the RYAH Smart Inhaler System as a medical device is a major step towards…

Continue Reading

FridayMar 04, 2022 12:14 pm

BioMedNewsBreaks – Why AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) Is ‘One to Watch’

AREV Life Sciences (CSE: AREV) (OTC: AREVF) is dedicated to delivering therapeutic interventions to public health through discovery, innovation and successful industry collaborations. Its leadership team is focused on driving discovery programs for clinical complexities demonstrated by malnutrition, the inflammatory response system and viral infectious diseases. “AREV’s business model leverages the core competency of producing proprietary compounds through its innovative extraction methodologies, scientific advisory board (‘SAB’), experienced staff, and executive leadership to drive its product pipeline,” reads a recent article discussing the company. “AREV’s strategy is to generate revenue from selling its branded products via its online technology platform, Medicine…

Continue Reading